COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Tracheobronchitis Prevention Trial (TRAMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01025921
Recruitment Status : Completed
First Posted : December 4, 2009
Last Update Posted : June 3, 2013
Information provided by (Responsible Party):
Efstratios Manoulakas, University of Thessaly

Brief Summary:
We aim to study whether the use of inhaled antibiotics may have an impact on the incidence of tracheobronchitis and pneumonia associated with the use of mechanical ventilation. The investigators hypothesize that this could be possible by decreasing the population of gram negative germs that colonize the lumen of tracheal tube and upper airways.

Condition or disease Intervention/treatment Phase
Tracheobronchitis Pneumonia Drug: colistin (Tadim) Other: inhaled normal saline Not Applicable

Detailed Description:

INTRODUCTION Gram-negative bacteria have recently become endemic in many ICUs around the world. Ventilator associated pneumonia (VAP) is relatively common and its parenteral treatment often leads to low and sub-therapeutic concentrations of antibiotics in the lung. Ventilator associated tracheobronchitis (VAT) is characterized by fever, purulent sputum, positive cultures of tracheal aspirates secretions and the absence of new pulmonary infiltrates on CXR. This entity is of particular interest because it is an intermediate step in the pathogenesis of VAP (between colonization and VAP itself) and prolongs mechanical ventilatory support. Inhaled antibiotics achieve high (both peak and trough) concentrations in respiratory secretions. Endobronchial antibiotics have been given to non-cystic fibrosis patients for prevention of VAP. Colistimethate sodium (colistin) given by instillation decreased the incidence of Gram-negative pneumonia and did not lead to the development of colistin resistant bacteria.


The study is a prospective open label randomized study which aims to clarify the effect of colistin to:

  1. The incidence of VAP The incidence of VAT
  2. Mechanical ventilation free days
  3. Incidence of multidrug resistant bacteria in tracheal aspirates cultures

METHODS Settings: The study will be performed in the ICU of the University of Larissa (12 beds).

Entry criteria: All intubated and tracheostomised patients, older than 18 years old with duration of intubation of 48 hours.

Exclusion criteria: 1) Purulent sputum within 48 hours from admission. 2) Pneumonia within 48 hours of intubation 3) New chest X ray infiltrate, 4) Advanced COPD that led to intubation 5) Pregnancy 6) Allergy to colistin 7) Resistance of the bacterial strain to colistin.

Tools: Randomization of the patients into two groups: the first group will receive nebulized colistin and the other no treatment. The initial dose is 1000000 units and it will be doubled after measurement of the drug concentration in tracheal secretions. The drug will start on admission and stop after 10 days.

All patients will be given the respiratory bundle measures (semi-recumbent position, daily interruption of sedation) as part of the usual daily practice of our ICU except otherwise indicated.

The severity of patients will be estimated by APACHE II score on admission and SOFA score thrice weekly. CPIS score as a screening tool for pneumonia will be estimated as well thrice weekly.

Tracheal aspirates cultures on admission and thrice weekly thereafter for the first two weeks and twice weekly thereafter.

The patients will be followed for thirty days to measure outcome.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Study of Inhaled Antibiotics for Prevention of Tracheobronchitis and Ventilator Associated Pneumonia
Study Start Date : November 2009
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Placebo Comparator: Inhaled colistin
They will receive inhaled colistin three times daily for 10 days.
Drug: colistin (Tadim)
500.000 units of inhaled colistin three times daily for 10 days

Placebo Comparator: Inhaled normal saline
Inhaled normal saline three times daily for 10 days
Other: inhaled normal saline
inhalation of 2,5cc Normal Saline via nebulisation

Primary Outcome Measures :
  1. Incidence of tracheobronchitis and ventilator associated pneumonia [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Ventilator free days and ICU length of stay [ Time Frame: 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All intubated and tracheostomized patients, older than 18 years old with duration of intubation of 48 hours.

Exclusion Criteria:

  • Purulent sputum within 48 hours from admission
  • Pneumonia within 48 hours of intubation
  • New chest X ray infiltrate
  • Advanced COPD that led to intubation
  • Pregnancy
  • Allergy to colistin
  • Resistance of the bacterial strain to colistin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01025921

Layout table for location information
University Hospital of Larissa
Larissa, Greece, 41110
Sponsors and Collaborators
University of Thessaly
Layout table for additonal information
Responsible Party: Efstratios Manoulakas, Professor and ICU Director Zakynthinos Epaminondas, University of Thessaly Identifier: NCT01025921    
Other Study ID Numbers: MARKAR161109
First Posted: December 4, 2009    Key Record Dates
Last Update Posted: June 3, 2013
Last Verified: May 2013
Keywords provided by Efstratios Manoulakas, University of Thessaly:
inhaled antibiotics
Ventilator associated tracheobronchitis
Ventilator associated pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Bacterial Agents
Anti-Infective Agents